#### EBMT Annual report 2023



ScienceEducationPatient Care & Advocacy Our SocietyOur Mission, Vision & ValuesEBMT Membership 2023Organisational Structure 2023Financial Highlights 2023EBMT Partners

## Breadcrumb

1. <u>Home</u>

# **Entity Print**



Annalisa Ruggeri CTIWP Chair Italy

## **Major achievements**

The CTIWP activities are constantly increasing in line with the advance in HCT, cell and gene therapy fields.

The collaboration with the different working parties and partner society (GoCART, EHA) is ongoing with the aim to harmonise the practice and the workload in the cell

therapy field. The activity in the harmonisation of the accreditation process for centres that perform CAR T therapies in collaboration with JACIE and GoCART, to avoid duplication of efforts (<u>Reduced CART site qualification workload for JACIE</u> <u>accredited centres | EBMT</u>).

The research activity is broad and dedicated to the immunogenetics to evaluate new factors on HLA expression level and typing able to improve transplant outcomes, and the role of HLA in the new post transplant cyclophosphamide approach. The immunomonitoring after CAR T as well the impact of possible exposure of antibiotics on the results of CART in patients with lymphomas, is under evaluation with surveys to dedicated centres. Another important field of research is to develop a consensus of the use of other cellular therapies, such as donor lymphocyte infusion according to the different donor types and stem cell source.

# **Principal research studies**

State-of-the art of immune monitoring procedures after chimeric antigen receptor Tcell therapies in EBMT centers Study type Closed Survey/Study Diseases All diseases Group Cellular Therapy & Immunobiology Working Party (CTIWP) Type of treatment CAR T Principal investigator Simona Pagliuca Survey on the use of DLI after allogeneic after allogeneic stem cell transplantation across EBMT centers Study type Closed Survey/Study Diseases All diseases Group Cellular Therapy & Immunobiology Working Party (CTIWP) Type of treatment Donor Leukocyte Infusion (DLI)

Principal investigator Nicole Santoro Potential factors influencing CAR-T cell manufacturing in terms of production failures and out of specification (OOS) products on behalf of EBMT - CTIWP Study type Closed Survey/Study Diseases All diseases Group Cellular Therapy & Immunobiology Working Party (CTIWP) Type of treatment CAR T Principal investigator Nina Worel Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone: A Retrospective Study on Behalf of the CTIWP Study type **Retrospective Studies** Diseases Acute Lymphatic Leukaemia (ALL) Acute Myeloid Leukaemia (AML) Chronic Lymphocytic Leukaemia (CLL) Chronic Myeloid Leukaemia (CML) Chronic Lymphocytic Leukaemia (CLL) Myelodysplastic (MDS) or MDS/MPN Group Cellular Therapy & Immunobiology Working Party (CTIWP) Type of treatment Allogeneic - Haploidentical Principal investigator Antoine Capes Defining protective immune cell subsets and subpopulations thresholds following allogeneic hematopoietic stem cell transplantation Study type **Retrospective Studies** Diseases

<u>All diseases</u> <u>Group</u> <u>Cellular Therapy & Immunobiology Working Party (CTIWP)</u> <u>Type of treatment</u> <u>Allogeneic</u> <u>Principal investigator</u> Marina Cavazzana

## **Key publications**

2023

Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey Group Cellular Therapy & Immunobiology Working Party (CTIWP) Other society 1st listed author P Comoli Journal Ann Oncol. 2023 Impact of allele-level HLA matching on outcomes after double cord blood transplantation in adults with malignancies Group Cellular Therapy & Immunobiology Working Party (CTIWP) Other society 1st listed author **Giancarlo Fatobene** Journal Blood Adv. 2023 Current use of fecal microbiota transfer in patients with hematologic diseases: a survey on behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT Group Cellular Therapy & Immunobiology Working Party (CTIWP) 1st listed author Giorgia Battipaglia

Journal

Bone Marrow Transplant.

<u>2023</u>

Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP) Group Cellular Therapy & Immunobiology Working Party (CTIWP) Infectious Diseases Working Party (IDWP) 1st listed author N Worel Journal Bone Marrow Transplant. 2023 Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party Group Cellular Therapy & Immunobiology Working Party (CTIWP) 1st listed author M A de Witte Journal Bone Marrow Transplant. See the full list of the CTIWP 2023 publications





2021 2022 2023

Oral presentations	4	2	7
Poster presentations	2	4	4
<b>Educational events</b>	5	7	7



<u>Event</u>

#### 49th Annual Meeting of the FBMT



<u>Event</u>

### EBMT-EHA 5th European CAR T-cell Meeting

Feb 09, 2023 - Feb 11, 2023 / Rotterdam & Online, Netherlands Discover more



#### <u>Event</u>

### Educational Meeting on Immunology and Cellular Therapy in Plasma Cell Disorders

#### Nov 24, 2023 - Nov 26, 2023 / Hamburg, Germany Discover more

- 49th Annual Meeting of the EBMT: Cell Therapy Day
- 49th Annual Meeting of the EBMT: CTIWP session
- 49th Annual Meeting of the EBMT: CTIWP Scientific Business Meeting
- DLI Harmonisation Workshop Lille
- CTIWP Scientific Business Meeting Hamburg

VISIT THE CTIWP WEBPAGE